The global Dasatinib Market was valued at USD 5.6 billion in 2025 and is projected to reach USD 7.6 billion by 2033, expanding at a CAGR of 4.3% from 2026 to 2033. The market is witnessing steady growth due to the increasing prevalence of hematologic cancers, particularly Chronic Myeloid Leukemia (CML) and Philadelphia chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL)....